Results 181 to 190 of about 40,669 (305)

Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second‐Line Treatment Failure

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Microsatellite stable/proficient mismatch repair (MSS/pMMR) colorectal cancer liver metastases (CRCLM) have limited treatment options after failure of second‐line systemic therapies. Hepatic artery infusion chemotherapy (HAIC) combined with targeted therapy and immunotherapy may offer improved outcomes.
Ran You   +9 more
wiley   +1 more source

Acute Intermittent Porphyria Triggered by COVID‐19 Mimicking Guillain–Barré Syndrome: A Diagnostic Challenge

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Acute intermittent porphyria (AIP) is a rare heme biosynthesis disorder in which the accumulation of neurotoxic porphyrin precursors precipitates neurovisceral attacks. Intercurrent infections, including coronavirus disease 2019 (COVID‐19), may trigger or exacerbate AIP and complicate diagnosis, as clinical manifestations can resemble those of
Payman Sadeghi   +5 more
wiley   +1 more source

Clinical and Radiological Outcomes Comparison of Degradable Starch Microspheres TACE with Idarubicin vs. Epirubicin Protocol in Patients with HCC. [PDF]

open access: yesDiagnostics (Basel)
Giurazza F   +10 more
europepmc   +1 more source

Secondary Dengue Infection Presenting With Kawasaki Disease–Like Features: A Diagnostic Dilemma in a 12‐Year‐Old Girl

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT In dengue‐endemic regions, prolonged fever with mucocutaneous findings may represent classical Kawasaki disease (KD), dengue‐associated KD‐like inflammation, or true concomitant disease. When KD cannot be confidently excluded, timely IVIG administration may be justified to prevent coronary complications.
Saad Bin Toufeeq   +5 more
wiley   +1 more source

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

open access: yesClinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy